Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11221799 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL381403 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2238752 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2238442 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2239219 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL23888724 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2237184 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL474241 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL7754974 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL3540013 | 1.00 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080079-B1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2018-07-25 | — | — | EP | claimed |
| US-20160318860-A1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2016-11-03 | — | — | US | claimed |
| EP-3080079-A1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2016-10-19 | — | — | EP | claimed |
| WO-2015086565-A1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2015-06-18 | — | — | WO | claimed |
| WO-2024044481-A1 | POLYOLEFIN ELASTOMER VITRIMER PREPARED WITH MULTI-FUNCTIONAL BORON-ESTER CROSSLINKERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3080079-B1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2018-07-25 | — | — | EP | disclosed |
| US-20160318860-A1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2016-11-03 | — | — | US | disclosed |
| EP-3080079-A1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086565-A1 | OXIDATION OF 2-MERCAPTOETHANOL | BASF SE (DE) | 2015-06-18 | — | — | WO | disclosed |
| US-5359139-A | Tertiary amine treatment | ALBEMARLE CORPORATION (US) | 1994-10-25 | — | — | US | disclosed |
| EP-0504628-A2 | Process for treating tertiary amines | ETHYL CORPORATION (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5136092-A | Process for treating tertiary amines | ETHYL CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| US-5118852-A | Tert-amine treatment | ETHYL CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| US-5113017-A | Process for treating tertiary amines | ETHYL CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| US-5107028-A | Process for treating tert-amines | ETHYL CORPORATION (US) | 1992-04-21 | — | — | US | disclosed |
| US-5103052-A | Tertiary amine treatment | ETHYL CORPORATION (US) | 1992-04-07 | — | — | US | disclosed |
| US-5103053-A | Process for treating tert-amines | ETHYL CORPORATION (US) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318860-A1 | OXIDATION OF 2-MERCAPTOETHANOL | HAO2, GPX4, SQOR | DNM1 2773/4885SPHK1 2256/4885CA12 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.